Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Euthymics Signs LOI To Acquire Dov Pharmaceutical
Dov believes that the contemplated $2m cash payment to shareholders represents approximately $0.015 per share of Dov common stock. If the transaction is consummated, it is anticipated that
Dov believes that the contemplated $2m cash payment to shareholders represents approximately $0.015 per share of Dov common stock. If the transaction is consummated, it is anticipated that
The company said that all ten of these patients, at all sampling time points, were found to have systemic interferon alpha-2b levels below the lower limit of detection
Perrigo had been sued by Adams Respiratory Therapeutics, a subsidiary of Reckitt Benckiser Group, the new drug application holder and patent owner. The US District Court for the
Diabecell is LCT’s treatment designed to normalise the lives of people with insulin dependent diabetes. Diabecell is implanted into patients and works by self-regulating and efficiently secreting insulin
The laser particle detection system allows accurate counting, sizing and data logging of shed particles from each drug-eluting stent during testing, giving a time course of shed particulates
RTS is expected to pay a minimum of $500,000. Hatch will join its Life Science division, which has successfully served the North American big pharma, biotech and academic
SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection
Taspoglutide is similar to the naturally occurring human hormone GLP-1, which plays a key role in blood glucose metabolism through a range of mechanisms. They include: improvement of
Under the five-year agreement, CRL will be Neuren’s preferred partner for clinical development. CRL presently is supporting Neuren’s phase II clinical research program with NNZ-2566, providing site monitoring,
Initial results suggest that the diagnostic accuracy of this new test will be greater than 97% for early stage ovarian cancer. The advice has come from the company’s